Nicholas A. Lopardo Sells 2,000 Shares of PerkinElmer, Inc. (PKI) Stock

PerkinElmer, Inc. (NYSE:PKI) Director Nicholas A. Lopardo sold 2,000 shares of the company’s stock in a transaction on Friday, November 30th. The shares were sold at an average price of $87.08, for a total value of $174,160.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Nicholas A. Lopardo also recently made the following trade(s):

  • On Monday, November 5th, Nicholas A. Lopardo sold 2,000 shares of PerkinElmer stock. The shares were sold at an average price of $82.12, for a total value of $164,240.00.

Shares of PKI stock opened at $90.60 on Tuesday. The company has a current ratio of 1.70, a quick ratio of 1.18 and a debt-to-equity ratio of 0.73. PerkinElmer, Inc. has a fifty-two week low of $69.21 and a fifty-two week high of $98.33. The stock has a market capitalization of $9.68 billion, a price-to-earnings ratio of 31.24, a PEG ratio of 1.94 and a beta of 1.12.

PerkinElmer (NYSE:PKI) last issued its earnings results on Wednesday, October 31st. The medical research company reported $0.90 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.02). PerkinElmer had a return on equity of 15.04% and a net margin of 4.71%. The firm had revenue of $674.30 million during the quarter, compared to analyst estimates of $676.72 million. During the same period in the previous year, the company earned $0.73 earnings per share. The business’s revenue for the quarter was up 21.7% on a year-over-year basis. Equities research analysts expect that PerkinElmer, Inc. will post 3.6 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, February 8th. Shareholders of record on Friday, January 18th will be given a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.31%. The ex-dividend date is Thursday, January 17th. PerkinElmer’s payout ratio is currently 9.66%.

Several research firms recently weighed in on PKI. UBS Group began coverage on PerkinElmer in a research report on Tuesday, October 9th. They set a “neutral” rating and a $100.00 price target on the stock. Deutsche Bank upped their target price on PerkinElmer from $88.00 to $93.00 and gave the stock a “hold” rating in a research report on Monday, September 10th. Barclays raised PerkinElmer from an “underweight” rating to an “equal weight” rating and upped their target price for the stock from $79.00 to $90.00 in a research report on Wednesday, September 5th. Janney Montgomery Scott lowered PerkinElmer from a “buy” rating to a “neutral” rating in a research report on Friday, November 2nd. Finally, Morgan Stanley upped their target price on PerkinElmer from $95.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 10th. Eight research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $87.84.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Riverhead Capital Management LLC boosted its stake in shares of PerkinElmer by 9.7% during the 2nd quarter. Riverhead Capital Management LLC now owns 6,795 shares of the medical research company’s stock worth $498,000 after acquiring an additional 602 shares in the last quarter. Paradigm Capital Management Inc. NY boosted its stake in shares of PerkinElmer by 0.9% during the 2nd quarter. Paradigm Capital Management Inc. NY now owns 79,750 shares of the medical research company’s stock worth $5,840,000 after acquiring an additional 750 shares in the last quarter. William Blair Investment Management LLC boosted its stake in shares of PerkinElmer by 6.8% during the 3rd quarter. William Blair Investment Management LLC now owns 12,076 shares of the medical research company’s stock worth $1,175,000 after acquiring an additional 765 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of PerkinElmer by 69.1% during the 3rd quarter. Tower Research Capital LLC TRC now owns 1,972 shares of the medical research company’s stock worth $191,000 after acquiring an additional 806 shares in the last quarter. Finally, Meag Munich Ergo Kapitalanlagegesellschaft MBH boosted its stake in shares of PerkinElmer by 7.5% during the 3rd quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 14,206 shares of the medical research company’s stock worth $1,369,000 after acquiring an additional 988 shares in the last quarter. Institutional investors own 94.82% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.com-unik.info/2018/12/04/nicholas-a-lopardo-sells-2000-shares-of-perkinelmer-inc-pki-stock-2.html.

About PerkinElmer

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil.

Further Reading: How do candlesticks reflect price movement?

Insider Buying and Selling by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit